Sign inJoin waitlistJoin the waitlist

Niharika Bansal Mettu

Associate Professor of Medicine · Duke Department of Medicine

Credentials: ·

History

Duke Department of Medicine
Present

Duke University School of Medicine
2008

Research

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial
JAMA Network Open · 2022 · First of 16 authors · Corresponding · 100 citations
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
Nature Medicine · 2023 · 95 citations
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Journal for ImmunoTherapy of Cancer · 2020 · 86 citations

Benedito Carneiro
4 papers
ER
Ezra Rosen
4 papers
Timothy Yap
4 papers
GC
Gregory Cote
3 papers
HH
Herbert Hurwitz
3 papers
John Strickler
3 papers
Al Benson
2 papers
Daniele Marin
2 papers
DS
David Spigel
2 papers
Desiree Morgan
2 papers
Devalingam Mahalingam
2 papers
FR
Francesca Rigiroli
2 papers

Clinical trials

Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer
Principal investigator · Withdrawn · Phase 2
Niharika Mettu
2018–2025
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Principal investigator · Completed · Phase 2
Academic and Community Cancer Research United
2017–2023